Kidney Week

Abstract: SA-PO663

Effectiveness of Elcatonin in Osteoporosis Patients Undergoing Hemodialysis

Session Information

• Bone and Mineral Metabolism: Clinical - II
  October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

• 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

• Lee, Jin ho, Bong Seng Memorial Hospital, Busan, Korea (the Republic of)

Jin ho Lee,

• Hwang, Seon Deok, Inha University College of Medicine, Incheon, Korea (the Republic of)

Seon Deok Hwang,

• Lee, Seoung Woo, Inha University Hospital, Inchon City, Korea (the Republic of)

Seoung Woo Lee,

• Park, Woo Yeong, Dongsan Medical Center, Daegu, Korea (the Republic of)

Woo Yeong Park,

• Kim, Jeong Ho, Daejeon St. Mary's Hospital, Daejeon, Korea (the Republic of)

Jeong Ho Kim,

• Kim, Hee yeoun, Bongseng hospital, Busan, Korea (the Republic of)

Hee yeoun Kim,

• Kim, Seong min, Dongrae Bongseng Hospital, Busan, Korea (the Republic of)

Seong min Kim,

• Oh, Joon Seok, Bong Seng Hospital, Korea, Dong-gu, Busan, Korea (the Republic of)

Joon Seok Oh,

• Lee, Dongyeol, Bong Seng Memorial Hospital, Busan, Korea (the Republic of)

Dongyeol Lee,

• Sin, Yong hun, Bong Seng Hospital, Busan, Korea (the Republic of)

Yong hun Sin,

• Kim, Joong Kyung, Bong Seng Memorial Hospital, Busan, Korea (the Republic of)

Joong Kyung Kim,

Background

Osteoporosis is a very serious risk factor for fractures that are related to patient mortality, Quality of Life worsening, and hospitalization in hemodialysis(HD) patients. In particular, treatment methods are very limited in HD patients compared with normal population. Therefore, most dialysis patients will not be able to treat osteoporosis, which can lead to bone fractures. On the other hand, elcatonin inhibits bone resorption and causes bone bone mineral density(BMD) elevation, but it is difficult to maintain bone mass and strengh. Although this medication reduces osteoporosis-induced pain, it is known to increase bone mass in some studies, and it can also be used in dialysis patients

Methods

We retrospectively studied 32 elecatonin-treated HD patients and 178 untreated HD patients. The follow up period was from 2005 to 2017, and the study was conducted at a single center. Osteoporosis was defined by WHO criteria (T score <-2.5). Elcatonin treatment group was diagnosed with osteoporosis, and 20 units were injected intramuscularly once a week after the patient 's consent was obtained. The primary outcome were Incidence of bone fracture, changes in BMD. Secondary outcomes was reduction of bone pain

Results

Fractures were observed in 7 patients (21%) in the Elcatonin group and 9 (11%) in the control group, but there was no statistical significance(p-value = 0.088). In 2013, the BMD in the Elcatonin group was 0.689 ± 0.039 which was statistically significantly lower than that of the control group of 0.937 ± 0.181(p-value <0.001). Also, in 2018, the BMD of the elcitonin group was 0.724 ± 0.08, which was statistically significantly lower than that of the control group of 0.9672 ± 0.186(p-value <0.001). There was no significant difference in reduction of bone pain between the two groups

Conclusion

Elcatonin was not effective in reducing the frequency of fractures or reducing bone pain in hemodialysis patients. Rather, the Elcatonin group had a further decrease in BMD compared with the control group. It is possible that the results have been observed to be worse because the Elcatonin group has been used on existing osteoporosis patients. However, Elcatonin seems to be ineffective in HD patients because it causes pain, increases drug costs and is not effective in treating osteoporosis.